Clinical Trial Update: A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating RIST4721 in hidradenitis suppurativa was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• RIST4721

Snippet

Sponsor: Aristea Therapeutics, Inc. | Conditions: Hidradenitis Suppurativa | Phase 2 | Status: TERMINATED | Results posted: 2023-06-13